CRNX CRINETICS PHARMACEUTICALS INC Product Launches 8-K Filing 2024 - Phase 3 Study Results Crinetics Pharmaceuticals announced positive results from a Phase 3 study for the treatment of acromegaly, with plans for commercialization of the drug.Get access to all SEC 8-K filings of the CRINETICS PHARMACEUTICALS INC